[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Beijing Jishuitan Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":178},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,44,72,101,128,156],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":4,"maxAge":4,"enrollmentInfo":16,"targetDuration":4,"studyType":19,"phases":20,"briefSummary":22,"conditions":23,"keywords":25,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100616899","a-study-on-the-effectiveness-of-preventive-extensive-release-of-the-rotator-interval-and-joint-capsule-to-reduce-postoperative-stiffness-in-arthroscopic-rotator-cuff-repair-100616899",false,"NCT07311616","A Study on the Effectiveness of Preventive Extensive Release of the Rotator Interval and Joint Capsule to Reduce Postoperative Stiffness in Arthroscopic Rotator Cuff Repair","Inclusion Criteria:\n\n1. Medium to small-sized (tear size \\\u003C3 cm) full-thickness supraspinatus muscle tears\n2. There was no shoulder joint stiffness before the operation. The range of motion of the joint was at least 160° for passive forward flexion under ROM anesthesia, 60° for external rotation when abduction was 0°, and equal to or greater than 60° for passive internal rotation at the level of the 10th thoracic vertebra\n3. About to undergo ARCR\n4. No history of trauma\n5. Patient consent to participate\n\nExclusion Criteria:\n\n1. There was a history of previous surgery on the ipsilateral shoulder\n2. Other injuries or lesions of the ipsilateral shoulder (such as glenohumeral arthritis, combined acromioclavicular joint dislocation, brachial plexus injury, etc.)\n3. It can not be completely repaired or even repaired during operation\n4. Have uncontrolled epilepsy or psychological illness\n5. Patients who were assessed as not suitable for inclusion in the study group","ALL",{"count":17,"type":18},50,"ESTIMATED","INTERVENTIONAL",[21],"NA","The incidence of rotator cuff injuries is high, especially among the elderly. With the aging of the population, the number of surgical patients has increased significantly. However, in the early stage after arthroscopic rotator cuff repair, a considerable proportion of patients are troubled by shoulder joint stiffness, which greatly affects the quality of life and satisfaction of patients after the operation. Despite this, there is still a lack of clear evidence-based medical evidence regarding whether preventive extensive shoulder release and joint capsule release during arthroscopic rotator cuff repair can effectively prevent or alleviate postoperative shoulder stiffness. To clarify this clinical issue, this project intends to conduct a single-blind randomized controlled trial (RCT). Before the operation, patients will be randomly divided into two groups under blinding conditions: the experimental group will receive arthroscopic rotator cuff repair surgery along with preventive extensive shoulder joint release and joint capsule release, while the control group will only receive arthroscopic rotator cuff repair surgery. After the operation, the investigators will conduct follow-up visits for 3 months, 6 months and 12 months for the two groups of patients, and perform magnetic resonance imaging (MRI) at the 12th month to assess the healing of the rotator cuff tendons. ASES score, Constant-Murley score, Visual Analogue Scale (VAS) pain score and active range (ROM) assessment were conducted before the operation and at the follow-up at 3 months, 6 months and 12 months after the operation. The occurrence of postoperative complications of the patients was counted at the last follow-up. Through this study, the investigators expect to provide scientific and effective guidance for the prevention of postoperative adhesions of the shoulder joint.",[24],"Supraspinatus Tear",[26,27,28,29,30],"Rotator cuff repair","Postoperative stiffness","Joint capsule release","Randomized controlled trial","Range of motion of the shoulder joint","NOT_YET_RECRUITING","2025-12-16",{"date":34,"type":35},"2025-12-31","ACTUAL",{"date":37,"type":18},"2025-12-22",{"date":39,"type":18},"2027-12-01",{"name":41,"class":42},"Beijing Jishuitan Hospital","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":15,"minAge":51,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":19,"phases":55,"briefSummary":57,"conditions":58,"keywords":61,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":43},"100604467","phase-3-a-study-of-collagen-scaffold-for-the-repair-of-elbow-cartilage-injury-100604467","NCT07149896","A Study of Collagen Scaffold for the Repair of Elbow Cartilage Injury","A Prospective Randomized Controlled Study Of Collagen Scaffold For The Repair Of Elbow Cartilage Injury","Inclusion Criteria:\n\n1. Subjects are between the ages of 18 and 55 (including 18 and 55 years old);\n2. Articular cartilage defect reaches Outerbridge grade III\u002FIV;\n3. The area of cartilage defect in a single site is 0.5cm²-2cm²;\n4. BMI 18≤BMI≤30;\n5. Clinically diagnosed cartilage defect requiring arthroscopic microfracture;\n6. Have not participated in other clinical trials within 3 months;\n7. Conservative treatment such as rest\u002Ftopical\u002Foral non-steroidal anti-inflammatory drugs for more than 3 months has not been effective\n8. Subjects fully understand the benefits and risks of this trial, are willing to participate and sign the informed consent form, and are able to cooperate with clinical follow-up.\n\nExclusion Criteria:\n\n1. Obvious narrowing of the elbow joint space or bone ankylosis formed between joints;\n2. Severe subchondral bone injury that cannot be undergoing microfracture surgery;\n3. Those with severe elbow deformity or systemic osteoarticular diseases;\n4. Secondary elbow arthritis with psoriasis, syphilitic neuropathy, brown yellow disease, metabolic bone disease;\n5. Elbow joint cartilage damage caused by joint fractures, infections, tumors, and immune diseases;\n6. Elbow joint tumors, rheumatoid, tuberculosis, suppuration and complications affecting the joint structure;\n7. Those who have undergone cartilage defect transplantation from bone marrow mesenchymal stem cell transplantation or other cartilage regeneration surgery within 12 months before surgery;\n8. Allergies, such as porcine protein allergy, past history or family history of autoimmune diseases;\n9. Those who regularly use sedatives, sleeping pills, tranquilizers or other addictive drugs;\n10. Combined with cardiovascular, cerebrovascular, liver, kidney and hematopoietic system and other serious primary diseases, mental illness;\n11. Those who cannot receive long-term and complex rehabilitation training after surgery;\n12. Women who are planning to have children, breastfeeding and pregnant women within 12 months;\n13. Those who have contraindications to MRI examination;\n14. Those who have special beliefs and cannot accept it (the product source is pig source);\n15. Those who are not suitable for inclusion by other researchers, such as those who cannot be judged for efficacy.","18 Years","55 Years",{"count":54,"type":18},90,[56],"PHASE3","The goal of this clinical trial is to test whether adding a collagen protein scaffold can improve cartilage repair in elbow joint injuries, compared to standard surgery alone. The study will enroll 90 patients (aged 18-55) with elbow cartilage damage who haven't responded to conservative treatments.\n\nThe main questions it aims to answer are:\n\n* Does the collagen scaffold help regenerate better-quality cartilage (measured by MRI scans at 3 and 6 months)?\n* Do patients experience better pain relief and elbow function after this combined treatment?\n\nResearchers will compare two groups:\n\n* Experimental group : Receives microfracture surgery + collagen scaffold implant\n* Active Comparator group : Receives microfracture surgery alone\n\nParticipants will:\n\n* Undergo arthroscopic surgery (either procedure)\n* Complete follow-up visits at 1 week, 1 month, 3 months, and 6 months\n* Have MRI scans and functional assessments\n* Report pain levels and daily activity limitations through questionnaires",[59,60],"Cartilage Defect","Elbow Injury",[62,63],"elbow cartilage defect","collagen scaffold","2025-08-24",{"date":66,"type":35},"2025-09-02",{"date":68,"type":18},"2025-08",{"date":70,"type":18},"2026-12",{"name":41,"class":42},{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":78,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":15,"minAge":80,"maxAge":81,"enrollmentInfo":82,"targetDuration":4,"studyType":84,"phases":4,"briefSummary":85,"conditions":86,"keywords":90,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":5},"100339417","china-health-big-data-100339417","NCT03699228","China Health Big Data","China Nationwide Multi Center Big Data Study on the Quantitative Computed Tomography (QCT) and Health Status of Check -up Population","China biobank","Inclusion Criteria:\n\nhealth check subjects 30-90 years old low dose chest CT scan\n\nExclusion Criteria:\n\npregnant women metal implant in the CT scan area","30 Years","90 Years",{"count":83,"type":18},30000,"OBSERVATIONAL","In this nationwide multi center study the investigators combine the low dose chest CT scan data with QCT technology, to measure the BMD of spine, VAT and liver fat in the health check subjects. The aim of this study is to evaluate the performance of QCT in the health check field, and further to evaluate the prevalence of osteoporosis, obesity and liver steatosis in health check population across China.",[87,88,89],"Osteoporosis","Obesity","Liver Steatoses",[91],"Bone mineral density, quantitative computed tomography, Osteoporosis, obesity, liver steatosis","RECRUITING","2025-08-13",{"date":95,"type":35},"2025-08-17",{"date":97,"type":35},"2017-12-01",{"date":99,"type":18},"2026-12-31",{"name":41,"class":42},{"id":102,"slug":103,"hasResults":11,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":107,"eligibilityCriteria":108,"healthyVolunteers":109,"sex":15,"minAge":110,"maxAge":111,"enrollmentInfo":112,"targetDuration":4,"studyType":84,"phases":4,"briefSummary":114,"conditions":115,"keywords":117,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":122,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":43},"100321161","chinese-second-hip-fracture-evaluation-100321161","NCT03461237","Chinese Second Hip Fracture Evaluation","Second Hip Fracture Evaluation in Chinese Elderly Patients Using Quantitative Computed Tomography","CSHFE","Inclusion Criteria:\n\n* a:Osteoporotic patients b:Osteoporotic hip fracture patients (femoral neck fracture and femoral trochanteric fracture) c: Be willing to and be able to join in the study and sighed the informed consent\n\nExclusion Criteria:\n\n* a:Under 47years old b:Non-surgical repair of hip fracture c:Pathologic fracture d:Violence-related trauma e:Bilateral hip implants or have hip replacement on the non-fractured side",true,"50 Years","95 Years",{"count":113,"type":18},3000,"1. To Compare overall rates of second hip fractures in both genders,\n2. To determine the effect of hip fracture on proximal femoral volumetric bone mineral density (vBMD), bone structure and muscle by quantitative computed tomography(QCT),\n3. To evaluate the contribution of QCT-image analysis to the prediction of the second hip fracture risk.\n4. To identify the differences between femoral neck fracture and trochanter fracture following hip fracture",[116,87],"Hip Fractures",[118,119,120,121],"Second Hip Fracture","Quantitative Computed Tomography","Bone structure","Muscle",{"date":95,"type":35},{"date":124,"type":35},"2017-05-01",{"date":126,"type":18},"2026-11",{"name":41,"class":42},{"id":129,"slug":130,"hasResults":11,"nctId":131,"briefTitle":132,"officialTitle":133,"acronym":4,"eligibilityCriteria":134,"healthyVolunteers":11,"sex":15,"minAge":51,"maxAge":4,"enrollmentInfo":135,"targetDuration":4,"studyType":19,"phases":137,"briefSummary":138,"conditions":139,"keywords":141,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":149,"startDateStruct":151,"completionDateStruct":153,"leadSponsor":155,"locationsCount":43},"100583108","the-efficacy-and-safety-of-venostan-in-promoting-postoperative-swelling-reduction-in-patients-with-ankle-fractures-100583108","NCT06872034","The Efficacy and Safety of Venostan in Promoting Postoperative Swelling Reduction in Patients With Ankle Fractures","The Efficacy and Safety of Venostan (Horse Chestnut Seed Extract Tablets) in Promoting Postoperative Swelling Reduction in Patients With Ankle Fractures: A Multicenter, Open-Label, Randomized Controlled Trial","Inclusion Criteria:\n\n* ≥18 year old, no gender restriction;\n* Diagnosed with ankle fracture confirmed by imaging data, AO classification: ---AO-43, AO-44-F3, AO-44;\n* Scheduled to undergo open reduction and internal fixation surgery;\n* Voluntary signing of the informed consent form.\n\nExclusion Criteria:\n\n* Pregnant or lactating women;\n* With contraindications to surgery;\n* With other severe combined injuries or soft tissue infections;\n* Severe multiple trauma: Injury Severity Score (ISS) \\> 16;\n* With concurrent fractures of the spine, pelvis, or ipsilateral or contralateral lower limbs;\n* Pathological fractures;\n* With peripheral vascular disease or deep vein thrombosis (DVT);\n* With severe impairment of heart, lung, liver, or kidney function or abnormal coagulation function;\n* Unable to walk independently before the injury;\n* With pre-existing lower limb edema (e.g., due to liver cirrhosis, kidney disease, etc.) before the injury;\n* With mental disorders or hyperalgesia;\n* Allergic to any component of the investigational drug;\n* Any contraindications that limit clinical evaluation and treatment of the patient;\n* Deemed unsuitable for inclusion in this study by the investigator.",{"count":136,"type":18},290,[21],"This study is a multicenter, open-label, randomized controlled trial planned to enroll patients with ankle fractures who meet the inclusion and exclusion criteria and are scheduled to undergo internal fixation surgery from the emergency and inpatient wards of multiple hospitals. General and disease-related data will be collected. All eligible patients must voluntarily sign an informed consent form after understanding and accepting the study. Successfully recruited participants will undergo internal fixation surgery at a scheduled time and then be randomly assigned to either the Venostan (horse chestnut seed extract tablet) group or the conventional treatment group. They will receive the corresponding treatments according to the study protocol. Follow-up assessments will include changes in ankle circumference, ankle range of motion, scale evaluation results, laboratory test results, and adverse events. The study aims to evaluate the effects of Venostasin in patients with ankle fractures undergoing internal fixation surgery, exploring its potential to promote postoperative reduction of ankle swelling, enhance early joint function recovery, and investigate its safety in postoperative fracture management.",[140],"Swelling\u002F Edema",[142,143,144,145,146,147],"Ankle fracture","Edema","Postoperative rehabilitation","horse chestnut seed extract","venostan","enhanced recovery after surgery","2025-07-14",{"date":150,"type":35},"2025-07-16",{"date":152,"type":35},"2025-04-16",{"date":154,"type":18},"2026-01-12",{"name":41,"class":42},{"id":157,"slug":158,"hasResults":11,"nctId":159,"briefTitle":160,"officialTitle":161,"acronym":4,"eligibilityCriteria":162,"healthyVolunteers":11,"sex":15,"minAge":51,"maxAge":163,"enrollmentInfo":164,"targetDuration":4,"studyType":84,"phases":4,"briefSummary":166,"conditions":167,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":172,"lastUpdatePostDateStruct":173,"startDateStruct":175,"completionDateStruct":176,"leadSponsor":177,"locationsCount":4},"100574261","long-term-outcomes-of-different-surgical-techniques-for-sacral-tarlov-cysts-a-prospective-cohort-study-100574261","NCT06756984","Long-Term Outcomes of Different Surgical Techniques for Sacral Tarlov Cysts: A Prospective Cohort Study","A Prospective Cohort Study on the Long-Term Outcomes and Prognostic Factors of Different Surgical Techniques for the Treatment of Sacral Tarlov Cysts","Inclusion Criteria\n\n1. Age 18-75 years.\n2. Diagnosed with symptomatic sacral Tarlov cysts confirmed by MRI.\n3. Presence of at least one of the following symptoms:\n\n   * Persistent sacral or lower back pain (VAS score ≥ 4).\n   * Neurological deficits such as lower extremity numbness or weakness.\n   * Bowel, bladder, or sexual dysfunction attributable to the cyst.\n4. Eligible for surgical intervention based on clinical evaluation.\n5. Willing and able to provide written informed consent.\n\nExclusion Criteria\n\n1. History of prior sacral Tarlov cyst surgery.\n2. Concurrent spinal conditions requiring separate surgical intervention.\n3. Active infection or systemic inflammatory disease.\n4. Severe comorbidities that increase surgical risk (e.g., advanced cardiac or pulmonary disease).\n5. Pregnancy or lactation.\n6. Inability to comply with follow-up requirements.\n7. Known allergy or contraindication to surgical materials (e.g., fibrin glue).","75 Years",{"count":165,"type":18},150,"Brief Summary\n\nThe goal of this observational study is to evaluate the long-term outcomes of different surgical techniques for sacral Tarlov cysts in adult patients aged 18-75 years diagnosed with symptomatic sacral Tarlov cysts. The main questions it aims to answer are:\n\n* Does one surgical technique result in better pain relief (measured by VAS score) and functional recovery (measured by JOA score) compared to others?\n* How do different surgical techniques impact the long-term recurrence rate and complication rate?\n\nResearchers will compare three surgical techniques:\n\n1. Partial cyst wall resection with nerve root sleeve plasty.\n2. Partial cyst wall resection with nerve root sleeve reinforcement and reconstruction.\n3. Autologous fat\u002Fmuscle with fibrin glue microscopic cyst filling.\n\nParticipants will:\n\n* Undergo one of the three surgical procedures based on clinical indications.\n* Complete preoperative and postoperative assessments, including pain and functional scoring, as well as MRI evaluations at baseline and during follow-up.\n* Participate in a follow-up program for up to 2 years to monitor outcomes and recurrence.",[168,169,170,171],"Sacral Tarlov Cysts","Symptomatic Sacral Cysts","Chronic Pain Related to Sacral Cysts","Neurological Dysfunction Associated With Tarlov Cysts","2025-05-12",{"date":174,"type":35},"2025-05-13",{"date":174,"type":18},{"date":99,"type":18},{"name":41,"class":42},""]